141 related articles for article (PubMed ID: 11453032)
1. Troglitazone and rosiglitazone inhibit the low density lipoprotein-induced vascular smooth muscle cell growth.
Gouni-Berthold I; Berthold HK; Weber AA; Seul C; Vetter H; Sachinidis A
Exp Clin Endocrinol Diabetes; 2001; 109(4):203-9. PubMed ID: 11453032
[TBL] [Abstract][Full Text] [Related]
2. Troglitazone and rosiglitazone induce apoptosis of vascular smooth muscle cells through an extracellular signal-regulated kinase-independent pathway.
Gouni-Berthold I; Berthold HK; Weber AA; Ko Y; Seul C; Vetter H; Sachinidis A
Naunyn Schmiedebergs Arch Pharmacol; 2001 Feb; 363(2):215-21. PubMed ID: 11218074
[TBL] [Abstract][Full Text] [Related]
3. Troglitazone inhibits mitogenic signaling by insulin in vascular smooth muscle cells.
Goetze S; Kim S; Xi XP; Graf K; Yang DC; Fleck E; Meehan WP; Hsueh WA; Law RE
J Cardiovasc Pharmacol; 2000 May; 35(5):749-57. PubMed ID: 10813377
[TBL] [Abstract][Full Text] [Related]
4. Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells.
Bruemmer D; Yin F; Liu J; Berger JP; Sakai T; Blaschke F; Fleck E; Van Herle AJ; Forman BM; Law RE
Circ Res; 2003 Aug; 93(4):e38-47. PubMed ID: 12881480
[TBL] [Abstract][Full Text] [Related]
5. PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells.
Goetze S; Xi XP; Kawano H; Gotlibowski T; Fleck E; Hsueh WA; Law RE
J Cardiovasc Pharmacol; 1999 May; 33(5):798-806. PubMed ID: 10226869
[TBL] [Abstract][Full Text] [Related]
6. Quercetin glucuronide prevents VSMC hypertrophy by angiotensin II via the inhibition of JNK and AP-1 signaling pathway.
Yoshizumi M; Tsuchiya K; Suzaki Y; Kirima K; Kyaw M; Moon JH; Terao J; Tamaki T
Biochem Biophys Res Commun; 2002 May; 293(5):1458-65. PubMed ID: 12054679
[TBL] [Abstract][Full Text] [Related]
7. Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair.
Schiefelbein D; Seitz O; Goren I; Dissmann JP; Schmidt H; Bachmann M; Sader R; Geisslinger G; Pfeilschifter J; Frank S
Mol Pharmacol; 2008 Oct; 74(4):952-63. PubMed ID: 18599600
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator-activated receptor gamma ligands inhibit mitogenic induction of p21(Cip1) by modulating the protein kinase Cdelta pathway in vascular smooth muscle cells.
Wakino S; Kintscher U; Liu Z; Kim S; Yin F; Ohba M; Kuroki T; Schönthal AH; Hsueh WA; Law RE
J Biol Chem; 2001 Dec; 276(50):47650-7. PubMed ID: 11598137
[TBL] [Abstract][Full Text] [Related]
9. Modulation of vascular smooth muscle cell growth by magnesium-role of mitogen-activated protein kinases.
Touyz RM; Yao G
J Cell Physiol; 2003 Dec; 197(3):326-35. PubMed ID: 14566962
[TBL] [Abstract][Full Text] [Related]
10. High density lipoproteins induce cell cycle entry in vascular smooth muscle cells via mitogen activated protein kinase-dependent pathway.
Nofer JR; Junker R; Pulawski E; Fobker M; Levkau B; von Eckardstein A; Seedorf U; Assmann G; Walter M
Thromb Haemost; 2001 Apr; 85(4):730-5. PubMed ID: 11341512
[TBL] [Abstract][Full Text] [Related]
11. Rosiglitazone regulates c-reactive protein-induced inflammatory responses via glucocorticoid receptor-mediated inhibition of p38 mitogen-activated protein kinase-toll-like receptor 4 signal pathway in vascular smooth muscle cells.
Liu N; Liu JT; Ji YY; Lu PP
J Cardiovasc Pharmacol; 2011 Mar; 57(3):348-56. PubMed ID: 21383592
[TBL] [Abstract][Full Text] [Related]
12. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
Díaz-Delfín J; Morales M; Caelles C
Diabetes; 2007 Jul; 56(7):1865-71. PubMed ID: 17416798
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization.
Murata T; He S; Hangai M; Ishibashi T; Xi XP; Kim S; Hsueh WA; Ryan SJ; Law RE; Hinton DR
Invest Ophthalmol Vis Sci; 2000 Jul; 41(8):2309-17. PubMed ID: 10892878
[TBL] [Abstract][Full Text] [Related]
14. Activation of extracellular signal-regulated kinase and c-Jun-NH(2)-terminal kinase but not p38 mitogen-activated protein kinases is required for RRR-alpha-tocopheryl succinate-induced apoptosis of human breast cancer cells.
Yu W; Liao QY; Hantash FM; Sanders BG; Kline K
Cancer Res; 2001 Sep; 61(17):6569-76. PubMed ID: 11522656
[TBL] [Abstract][Full Text] [Related]
15. Vascular smooth muscle cell proliferation requires both p38 and BMK1 MAP kinases.
Zhao M; Liu Y; Bao M; Kato Y; Han J; Eaton JW
Arch Biochem Biophys; 2002 Apr; 400(2):199-207. PubMed ID: 12054430
[TBL] [Abstract][Full Text] [Related]
16. Role for matrix metalloproteinase-2 in oxidized low-density lipoprotein-induced activation of the sphingomyelin/ceramide pathway and smooth muscle cell proliferation.
Augé N; Maupas-Schwalm F; Elbaz M; Thiers JC; Waysbort A; Itohara S; Krell HW; Salvayre R; Nègre-Salvayre A
Circulation; 2004 Aug; 110(5):571-8. PubMed ID: 15277330
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor-gamma ligands inhibit nuclear but not cytosolic extracellular signal-regulated kinase/mitogen-activated protein kinase-regulated steps in vascular smooth muscle cell migration.
Goetze S; Kintscher U; Kim S; Meehan WP; Kaneshiro K; Collins AR; Fleck E; Hsueh WA; Law RE
J Cardiovasc Pharmacol; 2001 Dec; 38(6):909-21. PubMed ID: 11707695
[TBL] [Abstract][Full Text] [Related]
18. Troglitazone inhibits angiotensin II-induced extracellular signal-regulated kinase 1/2 nuclear translocation and activation in vascular smooth muscle cells.
Goetze S; Xi XP; Graf K; Fleck E; Hsueh WA; Law RE
FEBS Lett; 1999 Jun; 452(3):277-82. PubMed ID: 10386606
[TBL] [Abstract][Full Text] [Related]
19. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia.
Law RE; Meehan WP; Xi XP; Graf K; Wuthrich DA; Coats W; Faxon D; Hsueh WA
J Clin Invest; 1996 Oct; 98(8):1897-905. PubMed ID: 8878442
[TBL] [Abstract][Full Text] [Related]
20. Critical role of c-Jun N-terminal protein kinase activation in troglitazone-induced apoptosis of human HepG2 hepatoma cells.
Bae MA; Song BJ
Mol Pharmacol; 2003 Feb; 63(2):401-8. PubMed ID: 12527812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
